A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE

References

• de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56(supplement 1):S75–S87. doi:10.1016/S0168-8278(12)60009-9. PMID:22300468.
   PubMedGoogle Scholar
• Zhong J-H, Rodríguez AC, Ke Y, Wang Y-Y, Wang L, Li L-Q. Hepatic Resection as a Safe and Effective Treatment for Hepatocellular Carcinoma Involving a Single Large Tumor, Multiple Tumors, or Macrovascular Invasion. Medicine. 2015;94(3):e396. doi:10.1097/MD.0000000000000396. PMID:25621684.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular Carcinoma. N Engl J Med. 2011;365(12):1118–1127. doi:10.1056/NEJMra1001683. PMID:21992124.
   PubMed Web of Science ®Google Scholar
• Farazi PA, Depinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674. doi:10.1038/nrc1934. PMID:16929323.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Ye N, Yao G. A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria. Ann Surg. 2011;254(5):837; author reply 837. doi:10.1097/SLA.0b013e318235e4eb. PMID:21997808.
   PubMed Web of Science ®Google Scholar
• Qi X, Liu L, Wang D, Li H, Su C, Guo X. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Oncotarget. 2015;6(34):36838–36859. doi:10.18632/oncotarget.5426. PMID:26451613.
   PubMedGoogle Scholar
• Liu K, Min X-L, Peng J, Yang K, Yang L, Zhang X-M. The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. J Clin Med Res. 2016;8(4):297–302. doi:10.14740/jocmr2496w. PMID:26985249.
   PubMedGoogle Scholar
• Zhang X, Wang K, Wang M, Yang G, Ye X, Wu M, Cheng S. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget. 2017;8(17):29416–29427.
   PubMedGoogle Scholar
• Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma. Gastroenterology. 2013;144(3):512–527. doi:10.1053/j.gastro.2013.01.002. PMID:23313965.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World Journal of Gastroenterology: WJG. 2015;21(36):10314–10326. doi:10.3748/wjg.v21.i36.10314..
   PubMed Web of Science ®Google Scholar
• Rai V, Abdo J, Alsuwaidan AN, Agrawal S, Sharma P, Agrawal DK. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Molecular and Cellular Biochemistry. 2018;437(1-2):13–36.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6(5):383. doi:10.1038/nri1842. PMID:16622476.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308. doi:10.1038/nrc2355. PMID:18354418.
   PubMed Web of Science ®Google Scholar
• Ding M, Wang Y, Chi J, Wang T, Tang X, Cui D, Qian Q, Zhai B. Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients. PLoS One. 2016;11(12):e0168798. doi:10.1371/journal.pone.0168798. PMID:28006010.
   PubMed Web of Science ®Google Scholar
• Siripongsakun S, Wei SH, Lin S, Chen J, Raman SS, Sayre J, Tong MJ, Lu DS. Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. J Gastroenterol Hepatol. 2014;29(1):157. doi:10.1111/jgh.12438..
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL and others. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Sci Transl Med. 2012;4(127):127ra37–127ra37. doi:10.1126/scitranslmed.3003689. PMID:22461641.
   PubMed Web of Science ®Google Scholar
• Semaan A, Dietrich D, Bergheim D, Dietrich J, Kalff JC, Branchi V, Matthaei H, Kristiansen G, Fischer HP, Goltz D. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. Virchows Archiv An International Journal of Pathology. 2017;470(2):185–196.
   PubMed Web of Science ®Google Scholar
• Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunological perspective. Clinical Cancer Research An Official Journal of the American Association for Cancer Research. 2013;19(24):6678–85. doi:10.1158/1078-0432.CCR-13-1721. PMID:24030702.
   PubMed Web of Science ®Google Scholar
• Crispe IN, Matthew G, Ingo K, Beena J, Bradford S, Sherry W. Cellular and molecular mechanisms of liver tolerance. Immunological Reviews. 2006;213(1):101. doi:10.1111/j.1600-065X.2006.00435.x. PMID:16972899.
   PubMedGoogle Scholar
• Fankhauser SC, Starnbach MN. PD-L1 limits the mucosal CD8(+) T cell response to Chlamydia trachomatis. Journal of immunology (Baltimore, Md.: 1950). 2014;192(3):1079–1090. doi:10.4049/jimmunol.1301657. PMID:24353266.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K and others. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. doi:10.1038/nm730. PMID:12091876.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847–856. doi:10.1158/1535-7163.MCT-14-0983. PMID:25695955.
   PubMed Web of Science ®Google Scholar
• Black M, Barsoum IB, Truesdell P, Cotechini T, Macdonald-Goodfellow SK, Petroff M, Siemens DR, Koti M, Craig AWB, Graham CH. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget. 2016;7(9):10557–10567. doi:10.18632/oncotarget.7235. PMID:26859684.
   PubMedGoogle Scholar
• Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62(6):1420–1429. doi:10.1016/j.jhep.2015.02.038. PMID:25733155.
   PubMed Web of Science ®Google Scholar
• Sumimoto H, Takano A, Teramoto K, Daigo Y. RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. PLoS ONE. 2016;11(11):e0166626. doi:10.1371/journal.pone.0166626. PMID:27846317.
   PubMed Web of Science ®Google Scholar
• Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression. Clin Cancer Res. 2004;10(15):5094–5100. doi:10.1158/1078-0432.CCR-04-0428. PMID:15297412.
   PubMed Web of Science ®Google Scholar
• Mu C-Y, Huang J-A, Chen Y, Chen C, Zhang X-G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28(3):682–688. doi:10.1007/s12032-010-9515-2. PMID:20373055.
   PubMed Web of Science ®Google Scholar
• Guo L, Li W, Zhu X, Ling Y, Qiu T, Dong L, Fang Y, Yang H, Ying J. PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. SpringerPlus. 2016;5(1):805. doi:10.1186/s40064-016-2513-x. PMID:27390646.
   PubMedGoogle Scholar
• Abbas M, Steffens S, Bellut M, Eggers H, Großhennig A, Becker JU, Wegener G, Schrader AJ, Grünwald V, Ivanyi P. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Med Oncol. 2016;33(7):80. doi:10.1007/s12032-016-0794-0. PMID:27317388.
   PubMed Web of Science ®Google Scholar
• Gao Q, Wang X-Y, Qiu S-J, Yamato I, Sho M, Nakajima Y, Zhou J, Li B-Z, Shi Y-H, Xiao Y-S and others. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. Clin Cancer Res. 2009;15(3):971–979. doi:10.1158/1078-0432.CCR-08-1608. PMID:19188168.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. Plos One. 2011;6(9):e23621. doi:10.1371/journal.pone.0023621. PMID:21912640.
   PubMed Web of Science ®Google Scholar
• Dai C, Lin F, Geng R, Ge X, Tang W, Chang J, Zheng W, Liu X, Ying L, Zhe Z. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget. 2016;7(9):10332–10344. doi:10.18632/oncotarget.7243. PMID:26871284.
   PubMedGoogle Scholar
• Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, Wang QJ, Pan K, Weng DS, Jiang SS, Tang Y. PD-L1 Expression as a Predictive Biomarker for Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma. Oncoimmunology. 2016;5(7):00–00. doi:10.1080/2162402X.2016.1176653..
   Web of Science ®Google Scholar
• Bai J, Mei PJ, Liu H, Li C, Li W, Wu YP, Yu ZQ, Zheng JN. BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro. Journal of Cancer Research & Clinical Oncology. 2012;138(6):991. doi:10.1007/s00432-012-1172-8..
   PubMed Web of Science ®Google Scholar
• Wang S, Wu X, Chen Y, Zhang J, Ding J, Zhou Y, He S, Tan Y, Qiang F, Bai J. Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clinical Cancer Research An Official Journal of the American Association for Cancer Research. 2012;18(10):2987. doi:10.1158/1078-0432.CCR-11-2863. PMID:22452940.
   PubMed Web of Science ®Google Scholar
• Guo X, Fan Y, Lang R, Gu F, Chen L, Cui L, Pringle GA, Zhang X, Fu L. Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast. Mod Pathol. 2008;21(9):1101–1107. doi:10.1038/modpathol.2008.72. PMID:18469794.
   PubMed Web of Science ®Google Scholar